Drug intelligence / Profile preview

CBG-391

Development stage: Preclinical
Lead developer: Carbiogene Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CBG-391 is an artificial intelligence (AI)-designed chimeric antigen receptor T-cell (CAR-T) therapy being developed by Carbiogene Therapeutics. It is currently in preclinical development for the treatment of lung cancer. The specific molecular target of the CAR-T construct has not been publicly disclosed.

Beyond the preview

Go deeper on CBG-391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBG-391.

Explore the full profile